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Objectives: Acute and chronic rejection remain unresolved problems after lung 
transplantation, despite heavy multidrug immunosuppression. In turn. the strong 
immunosuppression has been responsible for mortality and pervasive morbidity. It 
also has been postulated to interdict potential mechanisms of alloengraftment. 
Methods: In 48 lung recipients we applied 2 therapeutic principles: (1) recipient 
pretreatment with anti lymphoid antibody preparations (Thymoglobulin [SangStat, 
Fremont, Calif] or Campath [alemtuzumab; manufactured by ILEX Pharmaceuti-
cals, LP, San Antonio, Tex; distributed by Berlex Laboratories, Richmond, Calif]) 
and (2) minimal posttransplant immunosuppression with tacrolimus monotherapy or 
near-monotherapy. Our principal analysis was of the events during the critical first 
6 posttransplant months of highest immunologic and infectious disease risk. Results 
were compared with those of 28 historical lung recipients treated with dac1izumab 
induction and triple immunosuppression (tacrolimus-prednisone-azathioprine). 
Results: Recipient pretreatment with both antilymphoid preparations allowed the use of 
postoperative tacrolimus monotherapy with prevention or control of acute rejection, 
Freedom from rejection was significantly greater with Campath than with Thymoglobu-
lin (P = .03) or daclizumab (P = .05). After lymphoid depletion with Thymoglobulin 
or Campath, patient and graft survival at 6 months was 90% or greater. Patient and graft 
survival after 9 to 24 months is 84.2% in the Thymoglobulin cohort, and after 10 to 12 
months, it is 90% in the Campath cohort. There has been a subjective improvement in 
quality of life relative to our historical experience. 
Conclusion: Our results suggest that improvements in lung transplantation can be 
accomplished by altering the timing, dosage, and approach to immunosuppression 
in ways that might allow natural mechanisms of alloengraftment and diminish the 
magnitude of required maintenance immunosuppression, 
Traditional immunosuppressive strategies for organ transplantation have in-volved, from the time of operation, the use of potent. multidrug regimens, 
including a calcineurin inhibitor, high doses of prednisone, and an antime-
tabolite with or without a short course of antilymphoid antibody (induction), Despite 
the strong prophylactic immunosuppression, the incidence of acute rejection in the 
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first 6 to 12 months after lung transplantation has remained 
high. I Moreover, complications from the chronic immune 
depression and from drug-specific toxicities have been the 
rule rather than the exception, with infection-related mor-
tality the most common cause of death in the first 3 years 
after transplantation." As a result, the 1- and 5-year patient 
survivals reported from national and international lung 
transplantation registries are 73% to 77% and 42% to 45%, 
respecti vel y. 2.3 
It has also been suggested that excessive early postoper-
ative immunosuppression can potentially subvert postulated 
mechanisms of alloengraftment.4 Two therapeutic princi-
ples were applied in 48 lung recipients to avoid this self-
defeating consequence of treatment, beginning in June 
2002. First, the lung recipients were infused with a single 
large dose of a potent anti lymphoid preparation during the 
few hours preceding the operation or intraoperatively but 
before allograft reperfusion. The pretreatment was either 
with a rabbit antithymocyte globulin (Thymoglobulin; 
SangStat, Fremont, Calif; n = 38) or with the broadly 
reacting humanized anti-CD52 monoclonal antibody ale-
mtuzumab (Campath-IH [alemtuzumab], hereafter referred 
to as Campath; manufactured by ILEX Pharmaceuticals, 
LP, San Antonio, Tex; distributed by Berlex Laboratories, . 
Richmond, Calif; n = 10). Second, the recipients were 
treated after transplantation with tacrolimus monotherapy 
alone or in combination with very low doses of prednisone 
(usually 55 mg/d). 
Methods 
Recipient and Donor Demographics 
All adult patients undergoing single- or double-lung transplanta-
tion or heart-lung transplantation at the University of Pittsburgh 
between June 2002 and September 2003 were managed with the 
protocol described below, except for 5 recipients in whom there 
were logistical difficulties. From June 2002 through June 2003, 37 
recipients were pretreated with 4 to 7 mg/kg intravenous Thymo-
globulin; a 38th patient was added in September 2003. Between 
June 2003 and August 2003, the second cohort of 10 patients was 
pretreated with 30 mg of intravenous Campath instead of Thymo-
globulin. Results are compared with those of 28 unselected pa-
tients who underwent single- or double-lung transplantation or 
heart-lung transplantation at the University of Pittsburgh between 
December 2001 and June 2002 who were managed with ctacli-
zumab (Zenapax) induction, followed by triple-drug immunosup-
pressive therapy. 
The characteristics of the patients and donors in the 3 groups 
are shown in Table I. There was no significant difference between 
groups for any recipient or donor variable. The indications for 
transplantation were broader in the Thymoglobulin-treated and 
daclizumab-treated cohorts than in the Campath group (Table I). 
In the ThymoglobuJin-treated cohort, other risk factors included I 
(3%) patient with a preexisting, donor-specific, anti-class II anti-
body; 3 (8%) patients with scleroderma; I (3%) patient with cystic 
fibrosis with Burkholderia gladioli colonization; 2 (5%) patients 
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with sarcoidosis (odds ratio for death at I year of 2.03 by Inter-
national Society for Heart and Ling Transplantation [ISHL T] 
Registri); and one recipient of a simultaneous liver. 
Immunosuppressive Protocol 
The antibody infusions (Thymoglobulin, Cam path, or daclizumab) 
were initiated as soon as possible after confirmation of the accept-
ability of the donor organs. Thymoglobulin was begun slowly, 
with rate escalation every 30 minutes. Campath was infused at a 
steady rate over 2 hours. Patients who received Thymoglobulin or 
Campath were eoadministered I g of methylprednisolone to sup-
press cytokine reactions. In all patients 250 mg of methylpred-
nisolone was administered immediately before lung allograft 
reperfusion (I dose for single-lung or heart-lung recipients and 2 
doses for double-lung recipients). 
ThymoglobuJin-treated and Campath-treated patients were 
given twice-daily oral tacrolimus (Prograf; Fujisawa Healthcare, 
Inc, Deerfield, Ill) beginning on postoperative day I. Tacrolimus 
doses were adjusted to achieve a 12-hour trough level of 12 to 
15 ng/mL. All Thymoglobulin-treated patients received 5 mg/d 
prednisone beginning on postoperative day l. Five of the 10 
Campath-treated patients were given 5 mg/d (n = 4) or 7.5 mg/d 
(n = I) prednisone from postoperative day 1 because they were 
receiving corticosteroids preoperatively. The other 5 were treated 
with tacrolimus only. No patient received an antimetabolite. 
For patients who were given daclizumab, the protocol called for 
5 doses (I mg/kg each on day 0, posttransplant day 7, and post-
transplant weeks 2, 4, and 6). These patients also received a 
methylprednisolone taper beginning the day of transplantation and 
extending over 5 days from 240 mg/d to 40 mg/d, followed by 20 
mg of prednisone daily. Twice-daily tacrolimus (target 12-hour 
trough level of 15-20 ng/mL) and azathioprine (2-3 mglkg) were 
begun the day of transplantation. 
Diagnosis and Treatment of Rejection 
Acute rejection was diagnosed by means of histologic examination 
of transbronchial or open lung biopsy specimens according to the 
revised working formulation for the histologic classification of 
pulmonary allograft rejection.s The specimens were examined and 
graded by clinical pathologists according to our standard routine. 
Subsequent review of biopsy specimens was carried out at weekly 
conferences. Rejection was treated with corticosteroids (ie, IO-day 
oral prednisone taper [100 mg to previous baseline] or 1-2 doses of 
500- 1000 mg of methylprednisolone). In the Thymoglobulin- and 
Campath-conditioned patients, grade 2 acute rejection often was 
not treated in the absence of deterioration of allograft dysfunction 
unless there were histopathologic findings of issue injury. In con-
trast, all grade 2 acute rejection episodes were treated in the 
daclizumab cohort. 
Higher-grade rejections were treated with 2 to 3 doses of 
1000 mg of methylprednisolone, with occasional augmentation 
of maintenance steroids or the addition of other baseline agents. 
After Campath became available in the autumn of 2002, it was 
used to treat steroid-resistant rejection. A few patients were 
switched from tacrolimus to cyclosporine because of drug-
specific toxicity. 
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TABLE 1. Demographics of lung transplant recipients in the Thymoglobulin, Campath, and daclizumab groups 
Thymoglobulin Campath Daclizumab Pvalue 
Number 38 10 28 
Average age (y) 47 ± 13 (25-68) 55 ± 11 (37-70) 49 ± 14 (22-65) NS 
Sex (M/F) 17/21 7/3 15/13 NS 
Underlying disease NS 
CO PO 12 (37%) 2 (20%) 8 (29%) 
CF 8 (21%) 5 (18%) 
IPF 5 (13%) 4 (40%) 8 (29%) 
AlA deficiency 5 (13%) 1 (3%) 
Scleroderma/crest 3(8%) 1 (10%) 2 (7%) 
Sarcoidosis 2 (5%) 
PPH 1 (3%) 1 (3%) 
Pulmonary fibrosis 1 (3%) 
EG 1 (3%) 
OB/Retx 3 (30%) 1 (3%) 
Other 2(7%) 
Type of transplantation NS 
Single 17 (45%) 5 (50%) 12 (43%) 
Double 20 (53%) 4(40%) 15(54%) 
Heart, double lung 1 (10%) 
Double lung + liver 1 (2%) 
Living lung donor loba r 
CMV (D+/R-) 13/38 (34%) 2/10 (20%) 7/28 (25%) NS 
EBV (D+/R-) 2/38 (5%) 0/10 1/28 (3%) NS 
HLA mismatch 4.5 ± 1.3 5.2 ± 0.8 5.2 ± 0.9 NS 
PRA> 10% 1/38 (3%) 1/10 (10%) 2/28 (7%) NS 
Ischemia time (min) 345 ± 101 354 ± 85 329 ± 82 NS 
Donor age (y) 35 ± 15 (14-63) 39 ± 16 (11-62) 35 ± 15 NS 
COPD, Chronic obstructive pulmonary disease; CF. cystic fibrosis; IPF. idiopathic pulmonary fibrosis; A lA deficiency, "I-antitrypsin deficiency; PPH, primary 
pulmonary hypertension; £6, eosinophilic granuloma; OBIRetx, obliterative bronchiolitis retransplantation; CMV, cytomegalovirus; £BV, Epstein-Barr virus; 
PRA. panel reactive antibody. 
Assays of Lymphoid Depletion 
Patients receiving Thymoglobulin or Campath pretreatment were 
assessed for leukocyte subsets by means of flow cytometry at baseline 
(immediately before transplantation) and monitored for recovery at 
posttransplant days I, 7, 14, and 30 and months 3 and 6. 
Monitoring of Allograft Function 
In all cohorts surveillance spirometry and bronchoscopy with 
bronchoalveolar lavage and transbronchial biopsy were per-
formed at 2 and 8 weeks after transplantation and then every 2 
to 3 months. as well as when clinically indicated. 
Infection Monitoring and Prophylaxis 
Infection prophylaxis against cytomegalovirus (CMV) in Thy-
moglobulin- and Cam path-treated patients consisted of 450 to 
900 mg/d valganciciovir (Valcyte; Roche Laboratories, Nutley, 
NJ) for 6 months. For prophylaxis against fungus and yeast. 6 
mg/kg voriconazole (Vfend: Pfizer, New York. NY) was ad-
ministered intravenously every 12 hours for 2 doses, followed 
by 200 mg twice daily for 4 months. Pnellmocystis carinii 
prophylaxis was with one trimethoprim/sulfamethoxazole 
(TMP/sulfa) single strength tablet 3 times per week. 
Daciizumab-treated patients received valganciclovir and TMP/ 
sulfa as described but received 3 months of fluconazole (Diflucan, 
Pfizer) prophylaxis in lieu of voriconazole. 
Spaced Reduction of Tacrolimus 
In 17 Thymoglobulin-pretreated recipients who were 6 months 
or more after transplantation, an effort was made to reduce 
tacrolimus dosing to 4 times a week or 3 times per week. The 
decisions were made either as a search for the lowest level of 
treatment consistent with stable graft function in response to 
low-level nephrotoxicity or because of concern about smolder-
ing infection or incipient posttransplant lymphoproliferative 
disease. 
Informed Consent and Data Compilation 
Because the efficacy and safety of the immunosuppressive strategy 
had been demonstrated with other kinds of organ transplanta-
tion,6.7 the treatment regimen was deemed with the agreement of 
the University of Pittsburgh Institutional Review Board to be 
within the boundaries of standard therapy. The protocol was re-
viewed and authorized by the Presbyterian University Hospital 
Innovative Practices Committee and by the Pharmacy and Thera-
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Figure 1. The effect of Thymoglobulin and Campath on leukocyte subsets and their recovery after transplantation. 
The dashed line represents the value of 100 cells/ILL (see textl.16 Values are expressed as means ± SO. 
peutics Committee. Patients provided standard informed consent. 
In addition, all patients provided informed consent for enrollment 
under an institutional review board-approved protocol for studies 
not routinely performed in our conventional practice and for reo 
porting of outcomes. Data were collected in a prospective manner. 
Data integrity and safety and efficacy monitoring were ensured by 
means of establishment of a formal weekly review of cases. 
Because Campath cases were compiled recently, the comparisons 
between the therapeutic antibodies are limited to 6 months. 
Statistical Analysis 
The X2 statistic was used to determine the significance of nominal 
variables. Continuous variables were compared by either a Student 
t test or a Kruskal· Wallis test. All P values reported are 2 tailed. 
Survival and freedom· from· rejection analysis was determined by 
Kaplan-Meier actuarial analysis, and differences were compared 
with the log·rank test. Values are reported as means::':: SD. 
Results 
Tolerability of Pretreatment Protocol 
The antibody infusions were begun as soon as possible after 
determination of the acceptability of donor organs. Frequently, 
this preceded initiation of general anesthesia. All infusions 
were completed before graft reperfusion. Thymoglobulin was 
infused over an average of 225 ::!": 68 minutes (range, 120-433 
minutes), whereas Campath was infused over 2 hours. Both 
agents were generally well tolerated. In one patient with ob-
structive lung disease, significant bronchospasm began before 
starting Thymoglobulin and continued afterward. Thymo-
globulin was transiently stopped and later resumed at a slower 
rate, allowing almost a full dose (4 mg/kg) to be administered 
before allograft reperfusion. Another patient who received 
Thymoglobulin had significant hyperthem1ia, resulting in 
slowing of the rate of infusion. 
Immune Cell Reconstitution 
Pretreatment with 4 to 7 mg/kg Thymoglobulin resulted in 
profound depletion of T cells (CD3+) by postoperative day 1. 
T-cell counts remained less than baseline values for 3 months, 
with a gradual return toward nonnal levels by 3 to 6 months 
after transplantation (Figure 1, A). The CD8 population recov-
ered more rapidly than the CD4 population. Although CD8 cell 
counts returned to baseline by 1 to 3 months after transplan-
tation, CD4 cell counts remained at less than baseline value for 
up to 6 months (Figure 1, B·C). This pattern resulted in an 
inverted CD4/CD8 ratio that persisted up to 6 months after 
transplantation. B cells were not depleted by Thymoglobulin 
(Figure I, D). 
The level of T-cell depletion achieved was significantly 
greater and more sustained with Campath than with Thy-
moglobulin (Figure I, A) and included CD8 and CD4 phe-
notypes (Figure 1, B-C). CD4 (helper) cells were the most 
profoundly affected. The mean value for CD3+ cell counts 
depicted in Figure 1, A, at 6 months was due to high cell 
counts in 2 patients. The remainder of patients had cell 
counts that were 290 cells/fJ.L or less. 
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Figure Z. Kaplan-Meier plot of freedom from grade Z or greater rejection. ACR, Acute cellular rejection. 
Unlike Thymoglobulin, B cells were significantly de-
pleted with Cam path but returned to normal levels by 3 
months (Figure I, D). 
Rejection Episodes 
The incidence and overall burden of acute rejection was 
compared in patients who survived at least 2 weeks after 
transplantation (37/38 Thymoglobulin-treated patients, 
10/10 Campath-treated patients, and 26128 daclizumab-
treated patients). The percentage of patients with at least 
one episode of grade 2 or greater acute rejection in the 
first 6 posttransplant months was no different between the 
Thymoglobulin- and daclizumab-treated cohorts (25/37 
[68%] vs 17/26 [65%], P = not significant [NSJ). In 
contrast, the Campath cohort had significantly fewer pa-
tients with rejection (2110 [20%]; P = .008 vs Thymo-
globulin and P = .02 vs daclizumab). Similarly, there 
was no- difference in the percentage of patients with 
high-grade rejection E~grade 3) between the Thymo-
globulin- and daclizumab-treated cohorts (16/37 [43%] 
vs 12126 [46%], P = NS), whereas no Campath-condi-
tioned patients had high-grade rejection (P = .01 vs 
Thymoglobulin and P = .01 vs daclizumab). Figure 2 
shows the Kaplan-Meier plot of freedom from greater 
than or equal to grade 2 rejection, demonstrating the 
lower incidence of rejection in the Campath cohort. 
In addition, in those patients who experienced rejec-
tion, the number of rejection episodes was fewer in the 
Campath cohort compared with the Thymoglobulin and 
daclizumab cohorts. The average number of grade 2 or 
greater episodes of rejection per patient was 1.45 in the 
Thymoglobulin cohort and 1.15 in the daclizumab cohort 
(P = NS) but was significantly less in Campath-treated 
patients (0.2 episodes per patient [ie, a single episode of 
grade 2 rejection in 2 patients], P = .007 vs Thymo-
globulin and P = .03 vs daclizumab). Neither Campath-
preconditioned patient was treated with augmented im-
munosuppression for the grade 2 rejection. The frequency 
of high-grade rejection episodes was similarly no differ-
ent between Thymoglobulin- and daclizumab-treated pa-
tients (0.81 vs 0.57 episodes per patient, respectively; P 
= NS) but was significantly less in Campath-treated 
patients (0 episodes, P = .02 vs Thymoglobulin and P = 
.032 vs daclizumab). No patients in any group had his-
topathologic evidence of obliterative bronchiolitis during 
the first 6 months. 
Survival 
Six-month survival was not statistically different between the 
groups. Although survival in the Thymoglobulin and Campath 
groups was greater than our previous 3-year experience, the 
difference did not reach statistical significance (Figure 3). 
Six-month survival in the Thymoglobulin-treated cohort was 
97% (37/38). The only death during this period occurred on 
postoperative day 9 because of the sequelae of ischemia-
reperfusion injury. One patient required early retransplantation 
(postoperative day 54) for allograft dysfunction after transplan-
tation for sarcoidosis. The patient survived. Thus, graft survival 
at 6 months wa~ 95% (36/38). 
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Figure 3. Kaplein-Meier actuarial survival curves for the Thymoglobulin and Campath cohorts, as well as for the 
group of patients receiving lung transplants at the University of Pittsburgh Medical Center from July 1999 to June 
2002. Although pretreatment with either Thymoglobulin or Cam path with resultant management, as described in the 
text, resulted in a greater than 10% difference in 1-year survival between the Thymoglobulin and Campath groups 
and the historical group, the difference did not reach statistical significance. This is likely because of the small 
sample size. 
Six-month survival in the Campath-treated cohort was 
90% (9/10). The only death occurred on postoperative day 
23 in a 70-year-old recipient of a double-lung transplant (for 
emphysema) after an apneic episode on the ward. 
Six-month survival in the daclizumab group was 89% 
(25/28). 
Pulmonary Function 
The average forced expiratory volume in 1 second (FEV I) 
in the Thymoglobulin-treated cohort at 6 months was 70% 
:!: 19%, whereas that in the Campath-treated cohort was 
80% :!: 27% (P = NS). One single-lung recipient in the 
Thymoglobulin-pretreated group reached a peak FEV I at 2 
months after transplantation, with a subsequent decrease in 
values. Although transbronchial and open lung biopsies 
have not revealed any evidence of pathologic obliterative 
bronchiolitis, the FEV I values meet bronchiolitis obliterans 
syndrome 2 criteria. x This patient had preexisting donor-
specific anti-HLA class II antibody (Table I). No Campath-
treated patients met bronchiolitis obliterans syndrome 
criteria. 
Infection 
There was no significant difference in infection rates among 
the 3 groups, although there was a trend toward less CMV-
induced disease in the Campath cohort. Eighteen percent 
(5/28) of patients in the daclizumab group, compared with 
8% (3/38) in the Thymoglobulin group and 0% in the 
Campath group, had histologically proved CMV-induced 
disease (P = .23). There were 3 cases of Nocardia species 
(one each of Nocardia Nova. Nocardia jarcinica, and 
Nocardia asteroides complex) recorded in patients receiv-
ing Thymoglobulin pretreatment, whereas none occurred in 
the other groups (P = .19). 
Survival After 6 Months 
The potential follow-up for the 38 Thymoglobulin-
pretreated recipients is now 9 to 23 months. Although 37 
patients were alive at 6 months, 3 more deaths occurred by 
1 year (2 caused by sepsis and 1 caused by posttransplant 
lymphoproliferative disease), and 2 additional deaths oc-
curred after 13 and 16 months (viral influenza and chronic 
rejection, respectively). Thus, the I-year actuarial survival 
is 86%. Thirty-two (84.2%) of the original 38 patients are 
alive, with a mean follow-up of 17.1 :!: 4.0 months. Except 
for the death at 3 weeks of a 70-year-old emphysematous 
recipient, all of the other Campath-pretreated patients are 
alive, with a mean follow-up of 10.5 :!: 4.4 months (range, 
9-17 months). 
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Spaced Reduction of Tacrolimus 
In 16 of the 32 surviving patients pretreated with Thymo-
globulin, an attempt was made to reduce tacrolimus doses to 
3 or 4 times a week. Five of the 16 patients remain stable on 
spaced dosing after a mean period of 8.5 ::+: 2.8 months 
(range, 6- I 2 months). Weaning was discontinued in the 
other I I patients because of decreases in pulmonary func-
tion or because of histopathologic evidence of destructive 
immunity on biopsy. Despite augmentation of immunosup-
pression, full restoration of baseline function was achieved 
in only 3 of these patients. In contrast, the other 16 surviv-
ing recipients of the Thymoglobulin cohort who have been 
maintained on daily (twice a day or once a day dosing) 
tacrolimus monotherapy or near-monotherapy have had no 
deterioration in pulmonary function after a mean follow-up 
of 14.6 ::+: 3.7 months. 
Discussion 
There are obvious limitations to this study. Because it was 
a phase I-II study rather than a prospective randomized trial, 
definitive comparisons could not be made with contempo-
raneous (or, in our report, historical) control patients treated 
with conventional multiple drug immunosuppression. In 
addition, follow-ups are still short, particularly for the co-
hort of Campath-pretreated recipients. Nevertheless, it is 
noteworthy that our 6-month patient survival (97% and 90% 
in the Thymoglobulin and Campath cohorts, respectively) is 
competitive with the 89% 6-month survival with triple-drug 
immunosuppression in our immediately preceding experi-
ence and the benchmark 79% of the ISHLT registry? More-
over, current survival is 84.2% of our Thymoglobulin-
pretreated recipients with follow-ups of 9 to 23 months and 
has remained at 90% since postoperative week 3 in the 
Cam path-pretreated patients who are now 9 to 17 months 
after transplantation. In addition, no further deaths have 
occurred as additional patients (>40) have received trans-
plants with Campath preconditioning. These results were 
achieved without an increased risk of infection and, in fact, 
with a trend toward less CMV-induced disease in an uns-
elected series of patients who had a large representation of 
high-risk factors. 
Both Thymoglobulin and Campath are potent lymphoid-
depleting agents. Thymoglobulin9,j() has properties similar 
to the original polyclonal antilymphoid globulins that were 
introduced clinically nearly 40 years ago, and the more 
T-cell specific muromonab (OKT3). Campath was devel-
oped by Hale and Waldmann I I and first used for kidney 
transplantation by CaIne and colleagues. 12 In accord with 
reports by Knechtle,13 Kirk, 14 and their associates, our data 
demonstrate that Cam path has a more profound and pro-
longed lymphoid depletion than Thymoglobulin, including 
depression of the B-lymphocyte and natural killer lineages 
without causing major decreases in platelet counts. The 
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Cam path effect lasted for 6 months compared with the few 
weeks of Thymoglobulin. Because the extent and duration 
of T-cell depletion is thought to correlate with the avoidance 
of rejection, 15 including that of thoracic organs,16 the lower 
rate of rejection in the Campath cohort relative to the 
antilymphoid globulin group was not surprising. 
Moreover, the acute rejections were less severe in the 
patients pretreated with Cam path. The incidence of grade 2 
or higher acute rejection in the ThymogIobulin-treated pa-
tients was 66%, although the treated acute rejection rate was 
47%, The incidence of rejection was similar to that seen 
with standard triple immunosuppression without use of an-
tibody induction,17 as well as in some series in which 
antilymphoid globulins were administered postoperatively. 1 
In contrast, only 2 of the 10 Campath-pretreated patients 
had 1 episode each of grade 2 acute rejection (neither 
treated), and no patients had grade 3 rejection or higher, 
These patients were treated with steroid boluses or a short 
course of another agent but otherwise managed throughout 
with low maintenance immunosuppression. Five of the 10 
recipients treated with Campath never were administered 
anything but tacroIimus, whereas the other 5 also were 
given 5 mg/d or less prednisone, usually because the pa-
tients previously had received chronic steroid therapy. 
The timing of the lymphoid depletion in our patient 
deserves particular emphasis. The theory underlying our 
treatment strategy is that the seminal mechanism of organ 
alloengraftment is passenger leukocyte-driven clonal 
exhaustion-deletion, 18 an immune activation-dependent 
mechanism that can be variably eroded by heavy prophy-
lactic postoperative immunosuppression.4 Lymphoid deple-
tion before exposure to donor alloantigen was designed to 
avoid this pitfall, reduce the anticipated donor-specific re-
sponse into a more deletable range, and allow the safe use 
of minimum posttransplant immunosuppression. Thus our 
hypothesis was (and is) that organ engraftment is a state of 
variable partial tolerance that can be made more complete 
by modifying the timing and dosage of immunosuppression. 
Our view of organ engraftment and its relation to ac-
quired tolerance has been controversial. A large body of 
historical and recent work has led to alternative hypotheses 
to explain organ engraftment, acquired tolerance, or 
both. 19,20 These theories emphasize the importance of im-
munoregulatory T cells, other changes in the host immune 
response, or both that can downregulate alloimmune or 
autoimmune responses. In addition to T-cell immunoregu-
Iation, subsets of other special cells, changes in the host 
cytokine profile, or the development of enhancing antibod-
ies might playa role. In an attempt to foster these mecha-
nisms, lymphoid depletion has been done elsewhere at and 
after the time of transplantation. In recent trials Campath (or 
Thymoglobulin) was administered in 2 doses: the first in-
traoperatively and the second a few days later. Preliminary 
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results, especially after renal transplantation, have been 
encouraging. 12- 14 
Our strategy of lymphoid depletion before, rather than at 
or after, transplantation also has been shown to be effective 
for kidney, liver, and other kinds of organ transplanta-
tion.o.7,21 Implementing this regimen in a clinical setting of 
thoracic organ transplantation entailed 2 concerns. The first 
question was whether the use of minimalist posttransplant 
immunosuppression might result in an unacceptable loss of 
allografts to uncontrollable acute rejection. In the experi-
ence reported herein, the risk of short-term graft loss to 
acute rejection was no greater than with conventional im-
munosuppression in either the Thymoglobulin- or Campath-
pretreated recipients. 
The second question concerned the extent to which daily 
minimal maintenance immunosuppression could be sus-
tained after recovery from the lymphoid depletion or re-
duced further, without the penalty of breakthrough acute 
rejection or indolent chronic rejection. Studies in mice by 
Wu and colleagues22 have raised the possibility that recov-
ery from lymphoid depletion (homeostatic proliferation) 
might be associated with heightened long-term immune 
reactivity. The adverse consequences could include vigor-
ous later rejection that could become evident only with long 
follow-up. This issue can be tentatively addressed with 
observations in the Thymoglobulin-pretreated recipients, 32 
of whom survive after 17.1 ± 4.0 months (range, 9-23 
months). 
Fifteen of the 32 patients have been maintained on ta-
crolimus monotherapy for 14.6 ± 3.7 months (range, 9-22 
months), with no deterioration of graft function. An addi-
tional patient who had been maintained on twice-daily ta-
crolimus had a late rejection episode (II months) and re-
quired the addition of mycophenolate mofetil after 
treatment with steroids. In 16 others in whom spaced re-
duction of tacrolimus was attempted, this was tolerated by 
only 5 patients. Therefore we have concluded that attempts 
at spaced reduction of tacrolimus should not be made unless 
there is a specific reason to do so (eg, calcineurin inhibitor-
related renal dysfunction or an ongoing infection). A similar 
approach is being taken in the Campath-pretreated patients. 
We emphasize, however, that much longer follow-ups will 
be needed before the threat posed by chronic rejection can 
be fully evaluated. 
Randomized trials comparing the results with the dif-
ferent timing of antilymphoid antibody treatment, as well 
as comparisons of the lymphoid-depleting strategies with 
conventional immunosuppression, could lead to better 
care of lung recipients. In addition to analyses of clinical 
outcomes, detailed immune monitoring in such trials 
might help resolve disputes about the mechanisms of 
engraftment. Finally, the observations with lung trans-
plantation are expected to be generalizable to other or-
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gans, including the heart. We have pretreated 3 heart-
lung recipients with Campath (one included in the current 
report) and a recent heart-only recipient. All 4 patients 
have been free of rejection on tacrolimus monotherapy. 
We thank Terry L. Mangan for secretarial assistance and all 
members of the University of Pittsburgh Lung and Heart-Lung 
Transplantation Program for their dedication to patient care. 
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Discussion 
Professor Bruce Rosengard (Cambridge, United Kingdom). I 
would like to first congratulate Dr McCurry and his colleagues 
at Pittsburgh for the courage to apply the pioneering work of my 
colleague, Professor Sir Roy CaIne, to lung transplantation. As 
we all know. many of the early obstacles to lung transplantation 
have been overcome, but as you so rightly pointed out, the 
long-term outcomes caused by obliterative bronchiolitis remain 
a plague of the lung transplant recipient. To the extent that 
obliterative bronchiolitis is caused by an immune response, 
there is no patient group in transplantation that is more in need 
of better immunosuppressive therapy. 
Sir Roy's concept of Prope or almost tolerance has now been 
applied to several hundred liver or kidney recipients worldwide 
and is presently undergoing phase III testing to establish effi-
cacy in comparison with conventional triple-drug immunosup-
pression. Indeed, of Sir Roy's original 29 kidney patients 
treated with Campath and cyclosporine monotherapy, 26 remain 
on low-dose cyclosporine monotherapy, and the other 3 have 
had azathioprine and steroids added back. All patients at more 
than 5 years' follow-up now are doing very well clinically, with 
virtually normal renal function. 
If the majority of lung recipients are able to be treated with 
long-term monotherapy after an intense lymphocyte cytoreduc-
tion, this will be a major clinical advance because side effects 
and long-term complications will be reduced, even though the 
approach does not achieve true tolerance. I have 3 questions for 
the authors. 
In your article you attribute your clinical observations to 
clonal deletion or exhaustion of alloreactive T-cell clones; 
however, other clinical investigators have shown persistence of 
alloreactive clones after Cam path induction followed by tacroli-
mus monotherapy. Do you have evidence for either clonal 
deletion or exhaustion, or is it more likely that your protocol 
allows for the emergence of regulatory T cells, which mute the 
immune response? 
Dr McCurry. Thank you very much, Bruce, for your kind 
comments, and [ would also like to take the opportunity from a 
personal standpoint to thank you for your contributions and 
leadership in thoracic transplantation and personally for some 
support that you provided to me. 
Your question is a very good one. Our paradigm has been 
that of clonal exhaustion deletion, meaning that passenger leu-
kocytes migrate from the organ and go through a process with 
diminished initial alloimmune responses of clonal proliferation 
and ultimate exhaustion. This is based on historical work at our 
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institution, as well as some recent work that has been done in 
kidneys and livers. We have little data in the lung transplant 
population to demonstrate or suggest that this is definitely the 
mechanism by which this is occurring. 
We have done some early in vitro responses, and we do have 
2 patients who have diminished, not absent, responses, but who 
are hyporesponsive by mixed leukocyte reaction in vitro; how-
ever, there are certainly many other patients who maintain in 
vitro alloreactivity. In addition, we do have 2 patients who 
show a diminished frequency of donor-specific reactive T cells, 
as determined by means of limiting dilution assay, but again, 
many do not. Therefore, I think what we see is that for some 
reason, many of these patients are able to be maintained on 
low-dose monotherapy. 
The issue of whether we are inducing a regulatory T cell is 
a very good question also. As I am sure you well know, Stewart 
Knechtle and Alan Kirk have used Campath induction in kidney 
recipients, and I believe that both groups have recently reported 
the demonstration or a suggestion of development of a regula-
tory T cell in patients who have been treated with Campath who 
are now more than a year out from their transplantations. 
Most of our Cam path-treated patients are relatively early after 
transplantation at this point, but this is certainly an area that we are 
interested in and an area that we are beginning to look at, looking 
for both the CD4 +, CD25 + regulatory cell and the CDS + popu-
lation that the Columbia group has identified. In addition, we have 
also been looking for FOXP3, as well, which, as you know, is the 
marker of perhaps a tolerant phenotype. 
Professor Rosengard. Second, there is emerging evidence 
that T cells that repopulate a recipient after intense lymphocyte 
cytoreduction acquire the phenotype of memory or immunized 
cells, even in the absence of alloantigen. Do you think that this 
will limit the long-term efficacy of this approach because mem-
ory T cells are notoriously resistant to immunosuppressive 
therapy? 
Dr McCurry. Another very good question and something 
that we are concerned about. I think most of this work demon-
strating repopulation with a memory phenotype, as has been 
done by yourself, as well as Larry Turk and the group at Emory, 
which we have certainly read with interest, is an area that we 
are just now beginning to look at in our patients. We really do 
not have any data, but we are trying to look at the phenotype of 
the cells that do repopulate after both Thymog\obulin and 
Campath treatment. I do not know. It is hard to say. Certainly 
a mouse is not a man, and I think that Sir Roy Caine's data 
perhaps would argue that it is not a concern in human trans-
plantation, although certainly a kidney is not a lung either. 
Professor Rosengard. Finally, I am happy to see that you 
are planning to do a prospective randomized study. I was going 
to ask you, given the fact that hundreds of patients have been 
studied with phase I protocols in kidney and liver transplanta-
tion, why was it that you chose to do a phase I study in lung 
recipients as opposed to going for the full Monty? 
Dr McCurry. I think for several reasons. One is, obviously, 
as this group well knows, that lungs are difficult, and the early 
outcomes after lung transplantation have been notoriously dif-
ficult. We thought it best to obtain some safety data as an initial 
foray into this at a single center. I think it is also true that in 
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general the thoracic transplant community has not believed 
either from an immunologic or a safety standpoint a lot of the 
work that has been done in abdominal transplantation. A recent 
application of this, that is, the use of rapamycin after trials in 
kidneys, resulted in some bad outcomes in lung transplant 
recipients with bronchial dehiscence. Therefore we believed it 
was best to pursue a safety trial initially at our center, and then, 
on the basis of these data, we hope to proceed to a multicenter 
randomized trial. 
Dr Thomas M. Egan (Chapel Hill, NC). Dr McCurry, con-
gratulations on some outstanding results. My question does not 
relate to the immunologic aspect so much as a dramatic lack of 
problems with reperfusion injury. Most early mortality in lung 
transplantation relates to graft failure, and at least in your Campath 
group. it appears that you have avoided that. Is that just blind luck, 
or are you actually seeing a reduction in reperfusion injury as 
evidenced by ventilation duration, et cetera? 
Dr McCurry. Thanks very much, Tom. It is an area that we 
also have been interested in, and I am sure part of it is blind 
luck, but there are some data, as I am sure you are well aware, 
that at least Thymoglobulin, the polyclonal agents, decrease 
ischemia-reperfusion injury in kidney transplantation, and our 
anecdotal results thus far with Cam path have been that the early 
graft function is quite good. It is something that we are inter-
ested in at least from a clinical standpoint, comparing with 
some retrospective cohorts. 
Dr Egan. Does that imply that the T cell is involved in that 
reperfusion injury? 
Dr McCurry. There are certainly experimental data in animals 
to suggest that, and it might very well be. 
Dr Alec Patterson (St Louis, Mo). Ken, that was an excellent 
presentation, very nicely deli vered. If I understood or interpreted 
your slides correctly, the I-year early survival really was not much 
different than what is reported in most experienced centers. There-
fore although this strategy might have some relevance to bronchi-
olitis obliterans syndrome in later follow-up, I would have thought 
that we would see a reduction in early postoperative complications. 
Can you comment on that? 
Dr McCurry. Thank you, Alec, and thank you and your 
group for your contributions and your leadership. We only have 
Thymoglobulin-treated patients who are I year out, and our 
I-year survival in that patient population is 87%, so it compares 
favorably with ISHLT data. But as you suggest, many experi-
enced centers report I-year survival of greater than 80%. 
Certainly during the early course of using Thymoglobulin in 
this patient population, we went through a learning curve, and 
although we had one death in that group in the first 6 months-
therefore we had 37 of 38 survivors in the Thymoglobulin group at 
6 months-we did have another 3 deaths in the subsequent 6 
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months, and if I recall correctly, T believe that 2 of those deaths 
were due to sepsis and a third was due to a viral-related process, 
adult respiratory distress syndrome. It was a learning curve 
through that process. 
I believe our results right now with Campath have been quite 
good, and we do have about 37 patients who are doing well, and 
I anticipate we will have a very good I-year survival in that patient 
population. Again, only time will tell. 
Dr Duane R, Davis, Jr (Durham, NC). I rise to congratulate 
you for having the courage to try to change the paradigm of 
immunosuppression. Dr Alan Kirk, in his experience with Cam-
path in kidney transplant recipients, noted an acute rejection pro-
cess that was dominated histologically by macrophage and mono-
cytes. You have demonstrated that your patients treated with 
Campath have no T cells. What are the cells that are infiltrating the 
graft? As a secondary comment, what is the difference between 
peripheral and central depletion between Thymoglobulin and 
Campath? 
Peripheral depletion tends to be pretty good with both. How-
ever, central compartment depletion, which is probably going to be 
much more important in terms of being able to approach a tolero-
genic or at least a minimal immunosuppression strategy, probably 
is significantly better with Campath than with Thymoglobulin. 
Dr McCurry. Thank you, Duane. Those are both very 
interesting questions. I think, as you suggest, when Alan pub-
lished his data, of course he used Campath induction, I believe, 
if T recall correctly, 2 doses, about 40 mg, 50 mg, perhaps, with 
no baseline immunosuppression afterward. What we have typ-
ically seen in the Campath-treated patients is a bit of an early 
alloimmune response that has been a typical mononuclear T-
cell infiltrate. 
Now we have not done the immunostains and the typing with 
immunohistochemistry that Alan did in his study, but certainly the 
appearance of the grade 2 cases that we have seen look like other 
grade 2 cases that we have seen with Campath. Now that might be 
because perhaps we are not depleting as much as Alan was because 
we are giving a smaller dose, a single 30-mg dose as opposed to 
multiple doses up to 40 or 50 mg, but we really have not appre-
ciated a difference from a histologic standpoint. 
Your second question about central depletion is a very good 
question. Our paradigm has been to try to get all of the Cam-
path, or whatever agent we are using, in before allograft reper-
fusion, Again, we are using a smaller dose of Cam path than 
most of the abdominal groups have; I believe Alan has used up 
to 60 mg in his patient population, and Stewart perhaps used a 
similar dosing. Therefore, ideally we are depleting centrally. 
We do not have data to demonstrate that, but certainly from a 
peripheral standpoint, it takes a long time to reconstitute the 
CDS population, particularly the CD4 population. 
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